Evogene (TSE:EVGN – Get Free Report) had its price target lowered by research analysts at Ventum Financial from C$4.00 to C$3.00 in a research report issued to clients and investors on Friday,BayStreet.CA reports.
Evogene Price Performance
Evogene Company Profile
Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements.
See Also
- Five stocks we like better than Evogene
- What is the Shanghai Stock Exchange Composite Index?
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- Investing In Automotive Stocks
- MarketBeat Week in Review – 11/18 – 11/22
- Technology Stocks Explained: Here’s What to Know About Tech
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
